BioVaxys Technology Corp. (BVAXF)
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.
Industry: Biotechnology
BioVaxys Technology Corp.
Nasdaq bars a compliance period at 1:250
- 1:10Reverse splitSep 11, 202510 shares → 1
- 2:1Forward splitApr 28, 20201 share → 2
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $1K | $95K | $686K | $518K | $170K | $0 |
| Selling, General, and Administrative | $2.22M | $1.62M | $2.02M | $3.74M | $544K | $164K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $2.23M | $1.71M | $2.91M | $4.59M | $783K | $164K |
| Operating Income (EBIT) | -$2.23M | -$1.71M | -$2.71M | -$4.26M | -$719K | -$131K |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $0 | $18K | $11K | $5K | $98 | $0 |
| Other Income (Expense) | -$594K | -$3.77M | -$5.65M | -$341K | -$67K | -$24K |
| Income Before Tax (EBT) | -$2.82M | -$5.48M | -$8.36M | -$4.6M | -$786K | -$155K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $21 |
| Net Income | -$2.82M | -$5.48M | -$8.36M | -$4.6M | -$837K | -$164K |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -0.20 | -0.57 | -1.20 | -0.78 | -0.39 | -0.11 |
| Diluted EPS | -0.20 | -0.57 | -1.20 | -0.78 | -0.39 | -0.11 |
| Weighted Average OS | 19.57M | 13.41M | 9.82M | 8.29M | 2.82M | 2.13M |
| EBITDA | $0 | $0 | $0 | -$4.26M | -$719K | -$131K |
| EBITDA Margin | - | - | - | - | - | - |
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $151K | $696 | $101K | $423K | $1.73M | $163K | $11K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $151K | $696 | $101K | $423K | $1.73M | $163K | $11K |
| Accounts Receivable | $311K | $62K | $0 | $0 | $0 | $2K | $2K |
| Inventory | $0 | -$62K | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $62K | $0 | $0 | $0 | $53K | $0 |
| Total Current Assets | $927K | $81K | $509K | $623K | $2.18M | $218K | $24K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $0 | $0 | $0 | $0 | $0 | $53K | $53K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $5.27M | $5.27M | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $108K | $166K | $0 | -$53K | $0 |
| Total Long-Term Assets | $0 | $0 | $108K | $5.44M | $5.27M | $53K | $53K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | -$53K | $0 |
| Total Assets | $927K | $81K | $617K | $6.06M | $7.46M | $218K | $78K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $1.11M | $1.89M | $936K | $154K | $531K | $27K | $3K |
| Short-Term Debt | $49K | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $540K | $0 | $0 | $0 | $0 | $0 |
| Total Current Liabilities | $2.3M | $2.48M | $1.17M | $233K | $642K | $83K | $132K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.3M | $2.48M | $1.17M | $233K | $642K | $83K | $132K |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $19.28M | $15.68M | $12.16M | $10.52M | $7.66M | $407K | $53K |
| Retained Earnings | -$22.28M | -$19.46M | -$13.98M | -$5.72M | -$1.12M | -$279K | -$115K |
| Comprehensive Income & Other | $1.61M | $1.38M | $1.27M | $1.03M | $265K | $7K | $7K |
| Other Stockholders' Equity | $1.63M | $1.38M | $1.27M | $1.03M | $265K | $7K | $7K |
| Total Equity | -$1.37M | -$2.4M | -$551K | $5.83M | $6.81M | $136K | -$54K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $927K | $81K | $617K | $6.06M | $7.46M | $218K | $78K |
| Supplementary Data | |||||||
| Total Debt | $49K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Debt | -$102K | -$696 | -$101K | -$423K | -$1.73M | -$163K | -$11K |
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Operating Activities | ||||||
| Net Income | -$2.82M | -$5.48M | -$8.36M | -$4.6M | -$786K | -$164K |
| Depreciation & Amortization | $2.23M | $1.71M | $2.71M | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $215K | $107K | $356K | $811K | $248K | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | -$106K | $0 | $3K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $491K | $1.28M | $1.41M | -$357K | $131K | -$10K |
| Other Working Capital | -$347K | $277K | -$56K | $298K | -$451K | $9K |
| Total Working Capital Change | $38K | $1.56M | $1.36M | -$59K | -$320K | -$458 |
| Other Non-Cash Items | -$988K | $1.35M | $2.81M | $78K | -$16K | $3 |
| Net Cash from Operating | -$1.33M | -$752K | -$1.12M | -$3.77M | -$875K | -$164K |
| Investing Activities | ||||||
| Capital Expenditures | -$753K | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $29 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $44K | -$9K |
| Net Cash from Investing | -$753K | $0 | $0 | $0 | $44K | $0 |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | $264K | - | - |
| Common Stock Issuance | $2.25M | $654K | $790K | $2.18M | $2.12M | $354K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $0 | $534K | $272K | -$37K |
| Net Cash from Financing | $2.23M | $654K | $790K | $2.45M | $2.39M | $317K |
| Forex Effect | $2K | -$2K | $11K | $18K | $4K | $0 |
| Net Change in Cash | $150K | -$100K | -$322K | -$1.3M | $1.56M | $152K |
| Supplementary Data | ||||||
| Operating Cash Flow | -$1.33M | -$752K | -$1.12M | -$3.77M | -$875K | -$164K |
| Capital Expenditure | -$753K | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2.08M | -$752K | -$1.12M | -$3.77M | -$875K | -$164K |
| Cash at Beginning | $696 | $101K | $423K | $1.73M | $163K | $11K |
| Cash at End | $151K | $696 | $101K | $423K | $1.73M | $163K |